Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors
Summary
The purpose of this phase I, first-in-human, open-label, multicenter, dose-escalation study is to explore the safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.
General Information
NCT#: NCT04182516
Study ID: PARPA-293-001
Trial Phase: Phase I
Trial Sponsor: Nerviano Medical Sciences
Therapies Used in This Trial: NMS-03305293